I. COMPLETED
| Company Acquired (Symbol/ Country) | Acquired By or Merged With (Symbol/ Country) | Month Announced | Month Completed | Value (M)* | Terms/Details |
| ADL (Germany) | Matritech Inc. (NMPS) | 6/00 | 6/00 | $1 (initial payment) | Matritech acquired ADL through an exchange of 100 percent of the shares of ADL in return for an initial issuance of 37,153 shares of Matritech common stock; an additional payment, based on ADL s achievement of certain performance objectives during 2000, may be made during the first quarter 2001; this payment is expected to exceed 113,700 shares of Matritech common stock |
| Advanced Cell Technology Inc. (purchase of majority stake owned by Avian Farm) | ACT Group Inc. | 2/00 | 2/00 | ND | ACT acquired a majority of Avian Farm's interest in Advanced Cell, as well as stakes in two agbiotech companies (CIMA Biotechnology Inc. and Cyagra LLC); all three companies will remain separate, independently operating entities under the ACT Group |
| Agritope Inc. (AGTO) | Exelixis Inc. (EXEL) | 9/00 | 12/00 | $31 | Exelixis acquired Agritope by issuing 1.7M shares, which at the Dec. 8 opening stock price comes to about $31M; Agritope was renamed Exelixis Plant Sciences Inc. and is a wholly owned subsidiary of Exelixis |
| Algos Pharmaceuticals Corp. (ALGO) | Endo Pharmaceuticals Holdings Inc. (Switzerland; ENDP) | Nov-99 | 7/00 | $260 | Algos stockholders received one share of stock in Endo and one warrant to purchase additional shares for each share of Algos owned; warrants are exchangeable for an aggregate of 29.7M shares; Endo became a publicly held company through the merger and trades under the symbol ENDP (warrants are traded under ENDPW); Algos shareholders, with 17.9M shares, own 20 percent of the merged company |
| The 50% stake of Althin BioPharm Inc. owned by Axcan Pharma Inc. (Canada; TSE:AXP) | Baxter International Inc. (NYSE:BAX) | 5/00 | 5/00 | C$7.5 (US$5.0) | Baxter International acquired Axcan s 50 percent equity interest in Althin BioPharm Inc.; price of the transaction was C$7.5M (US$5.0M), paid in cash at closing |
| American Advanced Organics Inc. | Albany Molecular Research Inc. (AMRI) | 2/00 | 2/00 | $2.30 | Albany acquired AAO for $2.3M in cash and stock and will pay up to $0.8M in addition based on AAO's financial performance in 2000 and 2001 |
| Amrad Biotech (reagents unit of Amrad Corp. Ltd.; Australia; ASX:AML) | Chemicon International Inc. | 2/00 | 2/00 | A$14 (US$8.9) | Amrad sold its biotechnology reagents division, Amrad Biotech, to Chemicon for A$14M (US$8.9M); the deal includes all the assets of Amrad's biotech business |
| Anesta Corp. (NSTA) | Cephalon Inc. (CEPH) | 7/00 | 10/00 | $444 | Cephalon issued 6.7M shares to acquire Anesta; Anesta became a wholly owned subsidiary of Cephalon and its common stock will no longer be traded on Nasdaq |
| Apoptogen Inc. (Canada) | Exogen Neurosciences Inc. (Canada) | 4/00 | 5/00 | ND | The companies merged to form Aegera Therapeutics Inc., with operations centralized in Montreal |
| Aquila Biopharmaceuticals Inc. (AQLA) | Antigenics Inc. (AGEN) | 8/00 | 11/00 | $40 | Antigenics issued about 2.5M shares to acquire Aquila, or about 9 percent of the company; Aquila will operate as a wholly owned subsidiary of Antigenics |
| Atossa Healthcare Inc. | Nastech Pharmaceutical Co. Inc. (NSTK) | 8/00 | 8/00 | $2.50 | Shareholders of Atossa received one share of Nastech common stock for each 5.051 shares of Atossa common stock held; the total consideration paid for Atossa was 0.6M shares of Nastech common stock |
| Auxein Corp. | Mycotech Corp. | 1/00 | 1/00 | ND | The companies merged to form Emerald BioAgriculture Corp., which will focus on the development, manufacture and marketing of natural crop-protection and yield-enhancement products |
| Axys Advanced Technology (unit of Axys Pharmaceuticals Inc.; AXPH) | Discovery Partners International Inc. (DPII) | 5/00 | 5/00 | $60 | Axys Pharmaceuticals combinatorial chemistry subsidiary merged with Discovery Partners; Axys received approximately $60M in DPI stock for its interest in AAT |
| Bartels Inc. | Trinity Biotech plc (Ireland; TRIB) | 12/00 | 12/00 | $9.30 | Trinity acquired Bartels, a division of Intracel Corp., for $3.2M in stock and $6.1M in cash |
| BC Research Inc. (Canada) | Immune Network Ltd. (CDNX:IMM) | 5/00 | 8/00 | C$4.3 (US$2.9; value of common share component) | Immune Nework acquired a two-thirds controlling interest in BC Research by issuing 7.53M shares and an equal amount of Class A convertible preferred shares as payment for the company |
| BIO101 | Quantum Biotechnologies Inc. (Canada) | 4/00 | 4/00 | ND | Quantum's wholly owned subsidiary, Quantum Biotechnologies USA, and BIO101 merged to form a new entity called Q Biogene; terms ND |
| Bio/Can Group (Canada) | Genomics One Corp. (Canada; MSE:GNX) | 6/00 | 7/00 | C$3.1 (US$2.1) | Genomics One completed the C$3.1M (US$2.1M) acquisition of the Bio/Can Group of companies; the transaction included a C$1M (US$0.68M) cash payment, 0.14M shares of Genomics One capital stock at C$15.05 (US$10.22) per share, and 0.12M common share purchase warrants |
| BioChem ImmunoSystems Inc. (diagnostics unit of BioChem Pharma Inc.; Canada; BCHE) | Minority shareholder (ND) and management group | 1/00 | 3/00 | $54 | BioChem divested its diagnostics division and received a $54 million debenture to be paid out of future cash flows |
| BioKeys Inc. | BioQuest Inc. (Pink Sheets:BKYS) | 2/00 | 10/00 | ND | BioQuest and Biokeys merged to become publicly traded Biokeys Pharmaceuticals Inc. in a tax-free merger of equals; the new company trades under Biokeys Pharmaceuticals Inc. (Pink Sheets:BKYS); in conjunction with the merger, BioQuest conducted a reverse 1-for-2 stock split 7/00 and filed with the SEC to become a fully reporting company |
| Biomatrix Inc. (NYSE:BXM) | Genzyme Corp. (GENZ) | 10/00 | 12/00 | $259 (market capitalization as of 2/20) | Genzyme and Biomatrix formed Genzyme Biosurgery (GZBX), which has about 37M shares outstanding; holders of Genzyme Tissue Repair stock received 0.3352 of a share of Genzyme Biosurgery stock, and holders of Genzyme Surgical Products stock received 0.6060 of a share of Genzyme Biosurgery stock, for each share of their stock |
| Biomune Systems Inc. (OTC BB:BIME) | Donlar Corp. | 8/00 | 11/00 | $5.80 (Biomune s market capitalization) | Companies agreed to combine their businesses; Donlar owns about 95 percent of Biomune, with the resulting company operating under the Donlar name |
| BioNexus Genomics Inc. | Ashni Nutraceuticals Inc. | 1/00 | 1/00 | ND | Terms were ND |
| U.S. operations of British Biotech plc (UK; BBIOY) | Ilex Oncology Inc. (ILXO) | 3/00 | 3/00 | ND | Ilex's contract drug development subsidiary, Ilex Oncology Services Inc., acquired the operations of British Biotech's Annapolis, Md., office; Ilex will provide contract services necessary to complete ongoing clinical trials of British Biotech's anticancer drug, marimastat |
| Cambridge Discovery Chemistry (unit of Oxford Molecular Group plc; UK; LSE:OMG) | Millennium Pharmaceuticals Inc. (MLNM) | 7/00 | 7/00 | 35 (US$53) | Millennium acquired Cambridge Discovery Chemistry for a cash payment financed with a simultaneous private placement; the business will be renamed Millennium Pharmaceuticals Ltd. and will fully integrate with Millennium, while continuing to base operations in Cambridge, UK |
| Cambridge Drug Discovery Ltd. (UK) | Cambridge Genetics Ltd. (UK) | 1/00 | 1/00 | 8.25E (US$13.2) | The merger was accomplished through a stockfor-stock exchange; CGL also paid Oxford Molecular Group plc (LSE:OMG) 1.65M (US$2.64M) for its 20% stake; the deal was financed by raising 2.75M (US$4.4M) from CGL investors 3I Group, Alta Berkeley Associates and MVM |
| Cambridge NeuroScience Inc. (OTC BB:CNSI) | CeNeS Pharmaceuticals plc (UK; LSE:CEN) | 5/00 | 12/00 | $44 | CeNeS Pharmaceuticals and Cambridge NeuroScience merged with CeNeS, issuing 42.6M shares |
| Cancer Diagnostic Inc. | Lexon Inc. (OTCBB:LXXN) | 2/00 | 2/00 | $0.20 | Lexon acquired Cancer Diagnostic for $0.2M in cash and notes, made in lieu of Lexon's original plan to merge by issuing 0.5M shares to Cancer Diagnostic's owners |
| Cardiogene AG (Germany) | Intracardia Inc. | ND | 11/00 | ND | The companies merged to create a transAtlantic biopharmaceutical company focused on heart disease and cell transplantation; Cardiogene is changing its name to Cardion AG; corporate headquarters will be in Erkrath, Germany |
| Celtrix Pharmaceuticals Inc. (CTRX) | Insmed Pharmaceuticals Inc. (INSM) | Dec-99 | 5/00 | $131 | Each of the 37M shares of Celtrix was exchanged for one share in a newly formed holding company, and each share of Insmed was exchanged for three and one-half shares; shares in the merged company trade under the symbol INSM |
| Chalon Biotech Inc. (Canada) | Borealis Biosciences Inc. (Canada) | 8/00 | 8/00 | ND | The companies conducted a merger of equals to form Integrative Proteomics Inc. |
| ChiRex Inc. | Rhodia SA (France; NYSE:RHA) | 7/00 | 9/00 | $510 | Rhoida completed its acquisition of Chirex, purchasing shares at $31.25 in cash plus assumption of debt |
| Chiron Technologies Pty Ltd. (a.k.a. Mimotopes; Australian subsidiary of Chiron Corp.; CHIR) | MitoKor Inc. | 2/00 | 2/00 | ND | MitoKor acquired substantially all of the assets of Mimotopes; Chiron will collaborate by funding specific drug discovery projects over the next three years; other terms ND |
| Cistron Biotechnology Inc. (OTC BB:CIST) | Celltech Group plc (UK; LSE:CCH; NYSE:CLL) | 3/00 | 11/00 | $18 | Celltech completed its acquisition of Cistron, giving Cistron shareholders about 0.0202 of a Celltech American depositary share for each outstanding share of Cistron common stock; Cistron will no longer be traded publicly |
| CliniChem Development Inc. | BioChem Pharma Inc. (Canada; TSE:BCH; BCHE) | 10/00 | 12/00 | $32.90 | Biochem Pharma completed its purchase of outstanding shares of CliniChem, paying C$18.43 (US$12.129) per share |
| Cobra Therapeutics Ltd. (UK) | ML Laboratories plc (UK) | 2/00 | 2/00 | 8 (US$12.7) | Cobra shareholder ML Laboratories acquired the company in an all-share deal valuing Cobra at 8M (US$12.7M); in addition, ML will pay up to 12M (US19.2M) in milestones; Cobra's facilities will be retained |
| Collaborative BioAlliance Inc. (unit of The Collaborative Group Ltd.) | Dow Chemical Co. (NYSE:DOW) | 10/00 | 11/00 | ND | Dow acquired The Collaborative Group s Biotechnology Services Division, including all assets of Collaborative BioAlliance and Collaborative Smithfield Corp. |
| Coulter Pharmaceutical Inc. (CLTR) | Corixa Corp. (CRXA) | 10/00 | 12/00 | $570 | Corixa acquired all outstanding shares of Coulter in exchange for shares of Corixa valued at $570M; the purchase price is based on a fixed exchange ratio of 1.003 shares of Corixa common stock for each share of Coulter common stock outstanding |
| Crescendo Pharmaceuticals Corp. (CNDO) | ALZA Corp. (NYSE:AZA) | 10/00 | 11/00 | $100 | ALZA exercised its option to acquire all outstanding Class A Crescendo common stock; Crescendo stockholders will receive about $20.27 per share in cash |
| CytoGenesis Inc. | BresaGen Ltd. (Australia; AMEX:BGN) | 8/00 | 11/00 | ND | BresaGen issued about 7M shares and 2M options |
| Cytovia Inc. | Maxim Pharmaceuticals Inc. (MAXM) | 6/00 | 6/00 | $78 | Maxim acquired Cytovia by issuing 1.5M shares of common stock, or 7 percent of posttransaction shares outstanding |
| Dexter Corp. (NYSE:DEX) and Life Technologies Inc. (OTC BB:LTEK) | Invitrogen Corp. (IVGN) | 7/00 | 9/00 | $1.9B | Invitrogen purchased Life Technologies and Dexter Corp., paying in cash and stock to acquire all outstanding shares of Life Technologies; Invitrogen paid $62.50 per share, or about $1.5B, for all of Dexter s outstanding stock, and $60 per share, or another $400M, for the outstanding Life Technologies stock other than the shares owned by Dexter; the maximum cash portion will be about $410M for Dexter and about $105M for Life Technologies, or 28 percent of the aggregate merger consideration for each firm |
| Discovery Technologies Ltd. (Switzerland) | Discovery Partners International Inc. (DPII) | Jun-99 | 1/00 | ND | Discovery Technologies became a wholly owned subsidiary of Discovery Partners, retaining its headquarters in Switzerland |
| DNA Sciences Inc. | Genetic Vectors Inc. (OTC BB:GVEC) | Oct-99 | 2/00 | $2.50 | Genetic Vectors acquired DNA Sciences for 0.45M common shares |
| DNX Transgenic Sciences Inc. (subsidiary of MDS Inc.; NYSE:MDZ) | Xenogen Corp. | 9/00 | 11/00 | ND | Xenogen issued 3.5M shares of Series F preferred stock in exchange for all outstanding DNX shares |
| Dura Pharmaceuticals Inc. (DURA) | Elan Corp. plc (Ireland; NYSE:ELN) | 9/00 | 11/00 | $1.8B | Elan completed its acquisition of Dura; each share of Dura stock was exchanged for 0.6715 of an Elan American depositary share |
| Emerald BioStructures Inc. | MediChem Research Inc. | 6/00 | 6/00 | ND | MediChem, currently in registration for an IPO, issued 84,511 shares to acquire Emerald |
| Ethrog Biotechnologies Ltd. (Israel) | Invitrogen Corp. (IVGN) | 6/00 | 6/00 | $15.10 | Invitrogen issued 0.2M shares of its common stock for all of the capital stock of Ethrog in a transaction that is intended to be accounted for as a pooling of interests |
| Fielding Pharmaceutical Co. | Novavax Inc. (AMEX:NOX) | 10/00 | 12/00 | $31.50 | Novavax acquired 100% of the outstanding Fielding shares, paying $13M in cash and the remainder in shares of common stock; Fielding now is a wholly owned subsidiary |
| Fluorescience Ltd. (UK) | Cyclacel Ltd. (UK) | ND | 9/00 | ND | Cyclacel acquired Fluorescience in an all-cash acquisition, including equipment, intellectual property rights and the Fluorescience trademark; Fluorescience staff was relocated to Cyclacel s research and development center in Dundee; financial terms were ND |
| Gamera Bioscience Corp. | Tecan Group (Switzerland; SWX:TECN) | 7/00 | 7/00 | $10 | Tecan Inc. acquired Gamera Bioscience Corp. for $10M; the deal includes Gamera s lab-on-achip technology, LabCD, a compact disc that uses microscale fluid paths to combine highthroughput assaying and software to handle up to thousands of processes simultaneously |
| GelTex Pharmaceuticals Inc. (GELX) | Genzyme Corp. (GENZ) | 11/00 | 12/00 | $1B | Genzyme completed its acquisition of GelTex by issuing shareholders $22.59 in cash and 0.3818 of a share of Genzyme General for each share of GelTex |
| Genetic MicroSystems Inc. | Affymetrix Inc. (AFFX) | Sep-99 | 2/00 | $100 | Affymetrix acquired Genetic MicroSystems by issuing approximately 1M shares of common stock for all outstanding GMS shares; GMS will operate as a wholly owned subsidiary of Affymetrix and will maintain its facilities in Woburn, Mass. |
| GeneScape Inc. | SignalGene (Canada; TSE:SGI) | 2/00 | 3/00 | $15.20 | SignalGene acquired GeneScape for 6.6M shares, for a total of C$22.1M (US$15.2M) |
| Genion (Germany) | Evotec BioSystems AG (Germany; Neuer Markt:EVT) | 6/00 | 6/00 | DM5M (US$2.3) | Evotec acquired Genion for stock worth DM5M (US$2.3M) |
| Genopoietic SA (France) | Avax Technologies Inc. (AVXT) | 7/00 | 8/00 | $29 | Purchase price of up to $29M consisted of a combination of stock and options, payable upon achievement of milestones; the combination of stock and options will not exceed 3M shares |
| Genovo Inc. | Targeted Genetics Inc. (TGEN) | 8/00 | 9/00 | $67 | Targeted Genetics acquired Genova by issuing 6.63M shares to Genova shareholders |
| GSLI Life Sciences (division of GSI Lumonics Inc.; GSLI) | Packard BioScience Inc. (PBSC) | 8/00 | 10/00 | $120 | Packard BioScience acquired GSLI Life, including its bioinformatics software products, for $40M and approximately 4.6M shares of its common stock ($80M); the GSLI Life Sciences group will become a part of Packard BioChip Technologies LLC |
| Heaven's Door Corp. (HVDC) (now Paligent Inc.; PGNT) | Procept Inc. (PRCT) | Nov-99 | 1/00 | $67.20 | Procept issued 10.92M shares of common stock to Heaven's Door shareholders in exchange for 65% ownership of the new firm, HeavenlyDoor.com Inc. (HVDC); on the day the merger was completed, 1/28/00, Procept's stock closed at $6.15 per share, giving the deal a a value of $67.2M |
| HepaVec AG (Germany) | DeveloGen AG (Germany) | 5/00 | 10/00 | ND | The two companies merged to create a company focused on disease therapeutics based on developmental biology |
| DNA manufacturing subsidiary of Hybridon Inc. (OTC BB:HYBN) | Avecia LifeScience Molecules (UK) | 6/00 | 11/00 | $15 | Avecia acquired the DNA manufacturing business and related intellectual property of Hybridon for $15M; Avecia will supply GMP DNA for Hybridon and its associated operations through 2002 |
| ImmGenics Inc. (Canada) | Abgenix Inc. (ABGX) | 9/00 | 11/00 | C$110 (US$77) | Abgenix completed its acquisition of ImmGenics Inc., by exchanging US$77M of its stock for all of ImmGenics shares and options |
| Immune Complex Corp. | EVAX Technologies AG (Germany) | 12/00 | 12/00 | ND | EVAX acquired Immune Complex; EVAX will change its name to Apovia AG, and ICC will become Apovia Inc. |
| Incara Pharmaceuticals Corp. (INCR) | ND | Dec-99 | 1/00 | $10 | Incara sold its antibacterial drug discovery division to an undisclosed purchaser for cash payments in excess of $10M and $4M in future milestones |
| Infogen Medizinische Genetik GmbH (Germany) | ValiGen NV (the Netherlands) | 7/00 | 7/00 | ND | Valigen acquire all the outstanding common stock of Infogen through a share exchange |
| INH Technologies Inc. (subsidiary of Synsorb Biotech Inc.; Canada; SYBB) | MDS Inc. (Canada; TSE:MDS.A) | 3/00 | 3/00 | ND | MDS purchased INH for an undisclosed cash payment, plus future milestones and royalties; Synsorb expects that a revenue stream related to the sale could be generated within 12 months |
| IntraImmune Therapies Inc. | Abgenix Inc. (ABGX) | 11/00 | 11/00 | $9 | Abgenix acquired IntraImmune for $9M in cash |
| Kimeragen Inc. | ValiGene SA (France) | 2/00 | 2/00 | ND | Under merger of equals transaction, companies created ValiGen, with scientific operations in both Paris and Newtown, Pa., and an agricultural division in San Diego |
| Kinetix Pharmaceuticals Inc. | Amgen Inc. (AMGN) | 10/00 | 12/00 | $170 | Amgen acquired Kinetix for $170M in stock |
| LifePlan | HIV-VAC Inc. (OTC BB:HIVC) | 3/00 | 3/00 | $0.15 | HIV-VAC Inc. became a fully reporting company via acquisition of LifePlan for 0.1M shares of stock, for a total of $0.15M based on the 3/13/00 closing price |
| The Liposome Co. Inc. (LIPO) | Elan Corp. plc (Ireland; NYSE:ELN) | 3/00 | 5/00 | $575 | Elan Corp. completed its acquisition of Liposome following approval by stockholders; Liposome shareholders receive 0.3850 Elan American depositary shares and one contingent value right for each share of Liposome common stock; the agreement will provide for a cash payment by Elan to holders of up to $98M, with $54M contingent on certain approvals of Myocet in Europe and $44M contingent on Myocet reaching certain sales milestones outside the U.S. |
| LJL BioSystems Inc. (LJLB) | Molecular Devices Corp. (MDCC) | 6/00 | 8/00 | $348.80 | LJL BioSystems merged with Molecular Devices Corp.; each share of LJL common stock converts to 0.3 of a share of Molecular Devices common stock; Molecular Devices will issue about 4.45M shares in the transaction, valuing the deal at $348.8M based on the $78.375 closing price of the company s stock on 8/30; Molecular Devices will assume options and warrants to acquire about 675,000 additional shares; LJL becomes a wholly owned subsidiary of Molecular Devices |
| MarDx Diagnostics Inc. | Trinity Biotech plc (Ireland; TRIBY) | 3/00 | 3/00 | $4 | Trinity acquired MarDx for a consideration of $4M and will locate its marketing and sales staff for North and South America in MarDx's Carlsbad, Calif., facility |
| Assets associated with contract manufacturing business of Marathon Biopharmaceuticals Inc. (subsidiary of Ligand Pharmaceuticals Inc.; LGND) | CoPharma Inc. | 1/00 | 1/00 | $10 | CoPharma paid $10M in cash for the assets; under terms of the deal, Ligand subsidiary Seragen Inc. entered a long-term supply contract with CoPharma to manufacture Ontak, an FDA-approved cancer drug |
| Medeva Vaccines | PowderJect Pharmaceuticals plc (UK; LSE:PJP) | 8/00 | 10/00 | $79 | PowderJect acquired the Medeva vaccines business for $30M in cash and $32M as a balance payment on sales of the Fluvirin flu vaccine; the business will be merged into PowderJect s wholly owned subsidiary, Powderject Vaccines |
| Medeva plc (UK) | Celltech Chiroscience plc (UK) | Nov-99 | 1/00 | 563 (US$912) | Celltech acquired Medeva, offering 34 new shares for every 100 Medeva shares; Celltech shareholders now hold 56% of the combined company, which is called Celltech Group plc, with Medeva investors owning 44% |
| Medicomp Inc. and Telemedical Procedures LLC | United Therapeutics Corp. (UTHR) | 12/00 | 12/00 | $11.60 | United Therapeutics paid $8M in cash and issued about 260,000 shares, valued at about $3.6M |
| Megan Health Inc. | Avant Immunotherapeutics Inc. (AVAN) | 11/00 | 12/00 | $18 | Avant issued 1.9M shares to Megan s shareholders; Avant has 57M shares outstanding |
| Millennium Predictive Medicine Inc. (MPMx; subsidiary of Millennium Pharmaceuticals Inc.; MLNM) | Millennium Pharmaceuticals Inc. (MLNM) | 3/00 | 3/00 | ND | MPMx shareholders, including Becton Dickinson and Co. (NYSE:BDX), received one share of new Millennium common stock in exchange for five MPMx shares, subject to adjustment for the company's recent 2-for-1 stock split; additional terms were ND |
| Mimetrix (drug discovery unit of Peptide Therapeutics Group plc; LSE:PTH) | Medivir AB (Sweden) | 4/00 | 4/00 | ND | Medivir acquired Mimetrix for an undisclosed amount; completion of the transaction was contingent upon Medivir's raising 22M (US$35.2M) |
| Mitoscan Corp. | Harvard Bioscience Inc. (HBIO) | 12/00 | 12/00 | $0.30 | Harvard Bioscience acquired Mitoscan for upfront payments of $300,000, additional contingent payments and royalty payments based on future sales |
| Mitotix Inc. | GPC Biotech AG (Germany) | 3/00 | 3/00 | ND | GPC acquired Mitotix in an all-stock transaction to create GPC Biotech AG, which will be headquartered in Munich and operate U.S. facilities in Cambridge, Mass., and Princeton, N.J.; JSB Partners LP served as financial adviser to Mitotix |
| Moldyn Inc. | Structural Bioinformatics Inc. | 12/00 | 12/00 | ND | Structural Bioinformatics acquired Moldyn for an undisclosed amount |
| Mycota Biosciences Inc. (Canada) | Elitra Pharmaceuticals Inc. | 10/00 | 12/00 | $19.34 | Elitra issued 5.95M shares to acquire Mycota, which will continue as a wholly owned subsidiary of Elitra |
| ND | GenSci Regeneration Sciences Inc. (Canada) | 4/00 | 4/00 | ND | GenSci created a new subsidiary, GenSci OCF Inc., through the acquisition of a majority stake in an undisclosed privately held oral cranio-facial company located in Montreal |
| Nanodesign Inc. (Canada) | SignalGene Inc. (Canada; TSE:SGI) | 5/00 | 6/00 | C$15 (US$10.2) | SignalGene Inc. acquired Nanodesign in a transaction valued at about C$15M (US$10.2M) involving the issue of about 5.4M common shares of SignalGene and about 1.4M warrants to Nanodesign s shareholders, plus an additional C$2M in cash to Nanodesign s controlling shareholder, Guard Inc. |
| NEN Life Science Products | PerkinElmer Inc. (NYSE:PKI) | 6/00 | 7/00 | $400 | PerkinElmer acquired NEN from an investor group led by Genstar Capital LLC for approximately $400M; transaction will be accounted for as a purchase |
| Neomorphic Inc. | Affymetrix Inc. (AFFX) | 10/00 | 10/00 | $70 | Affymetrix issued about 1.4M shares of its stock for all outstanding Neomorphic shares and stock options |
| Neurotrophic Bioscience Inc. (Canada) | IGT Pharma Inc. (Canada; CDNX:IGT) | 10/00 | 11/00 | US$9 | IGT acquired all issued and outstanding shares of Neurotrophic, issuing 10.734M shares in a merger of equals and renaming the new company Prescient NeuroPharma Inc. |
| NMT Medical Inc. (NMTI) | Integra LifeSciences Holding Corp. (IART) | 3/00 | 3/00 | $12 | NMT sold several product lines from its neurosciences division, including certain assets and liabilities for $12M in cash |
| North American Vaccine Inc. (AMEX:NVX) | Baxter International Inc. (NYSE:BAX) | Nov-99 | 6/00 | $380 | NAV shareholders received $6.73 per share comprising $6.70 in Baxter common stock and 3 cents in cash; for each share of NAV stockholders received 0.1021 shares of Baxter |
| Novalon Pharmaceuticals Corp. | Karo Bio (Sweden; SSE:KARO) | 3/00 | 5/00 | $107 | Novalon was consolidated with Karo Bio as of 5/1; Karo issued 2.2M shares to make the acquisition; Novalon will operate as a wholly owned subsidiary of Karo with no staffing or directional changes anticipated |
| Novopharm Ltd. (Canada) | Teva Pharmaceutical Industries Ltd. (Israel; TEVA) | Dec-99 | 4/00 | $266 | Dan Family Holdings, the sole shareholder of Novopharm, received equity securities representing approximately 6.2% of Teva's outstanding shares, to be held by a trustee in Israel and released in installments over the next 18 months |
| Ontogeny Inc. and Reprogenesis Inc. | Creative BioMolecules Inc. (CBMI) | 2/00 | 8/00 | $434 | Creative BioMolecules, Ontogeny and Reprogenesis merged to form Curis Inc., which began trading under the symbol CRIS on 8/1; approximately 43 percent of the company s outstanding shares are owned by former Creative BioMolecules stockholders, 38 percent by Ontogeny stockholders and 19 percent by Reprogenesis shareholders |
| Operon Technologies Inc. | Qiagen NV (the Netherlands; Neuer Markt:QIA) | 6/00 | 6/00 | $110 | Qiagen completed its $110M acquisition of Operon Technologies; Qiagen issued about 0.6M shares of stock and assumed options on Operon s common stock exercisable for another 0.1M shares of Qiagen stock |
| Ophidian Pharmaceuticals Inc. (OPHD) | Promega Corp. | 9/00 | 11/00 | $70 | Promega assumed $2M of Ophidian debt obligations, real estate lease obligations and paid $1.2M to Ophidian, plus up to $250,000 90 days after the closing, depending upon certain post-closing factors; Promega also acquired Ophidian s portfolio of patents and other intellectual property |
| Software business of Oxford Molecular Group plc (UK; LSE:OMG) | Pharmacopeia Inc. (PCOP) | 8/00 | 9/00 | $27 | Pharmacopeia purchased the business for $27M, consisting of cash and the assumption of certain liabilities; the acquisition will be accounted for as a purchase |
| Opticon Inc. | Immune. Response Inc. (OTC BB:IMUN) | 1/00 | 2/00 | $3 | Immune Response acquired Opticon and is now operating through its wholly owned subsidiary, Opticon Medical Inc.; funding for the transaction was provided by a 6% convertible debennture offering for $3M |
| Oxford Asymmetry International plc (UK; LSE:OAI) | Evotec BioSystems AG (Germany; Neuer Markt:EVT) | 7/00 | 12/00 | 316 (US$475) | OAI shareholders received 0.1287 Evotec shares for each OAI share held; the offer values OAI at 722 pence per share, a premium of approximately 46 percent; OAI shareholders will own about 31 percent of the merged company |
| Paracel Inc. | Celera Genomics Group (NYSE:CRA) | 3/00 | 6/00 | $225 | All of Paracel s equity was exchanged for 2.26M shares of Celera common stock; the transaction was structured as a tax-free reorganization |
| Pathogenesis Corp. (PGNS) | Chiron Corp. (CHIR) | 8/00 | 9/00 | $700 | Chiron acquired Pathogenesis, paying $38.50 per share in cash for all outstanding Pathogenesis shares |
| Pharma-G Inc. | Theratechnologies Inc. (Canada; TSE:TH) | 9/00 | 10/00 | C$7.5 (US$5) | Theratechnologies issued half a million shares at C$15 each |
| Pharmazyme (division of Immune Complex Corp.) | PPD Discovery (wholly owned subsidiary of PPD Inc.; PPDI) | 2/00 | 2/00 | ND | PPD acquired the assets of Pharmazyme, which develops, makes and markets drug metabolism reagent products and services |
| Pharmatec SpA (unit of Aspen Healthcare Group) | Eurand | 6/00 | 6/00 | $13.50 | Eurand acquired Pharmatec for approximately $13.5M |
| PPGx Inc. | DNA Sciences Inc. | 12/00 | 12/00 | ND | DNA Sciences acquired PPGx by issuing preferred stock to PPD Inc. and Axys Pharmaceuticals Inc., in exchange for all outstanding capital stock and options in PPGx |
| Praelux Inc. | Amersham Pharmacia Biotech (life sciences business of Nycomed Amersham plc; UK; NYSE:NYE; and Pharmacia Corp.; NYSE:PHA) | 2/00 | 2/00 | ND | Amersham Pharmacia signed a definitive merger agreement to gain 100% of Praelux |
| Principia Pharmaceutical Corp. | Human Genome Sciences Inc. (HGSI) | 9/00 | 9/00 | $120 | HGS completed the acquisition of Principia in a stock swap, with a price based on a 20-day average of HGS s share price for all outstanding Principia shares and options; Principia became a wholly owned subidiary |
| ProFound Pharma A/S (Denmark) | Maxygen Inc. (MAXY) | 4/00 | 8/00 | $63.20 | All equity interests of ProFound were exchanged for 1.1M shares of Maxygen common stock and options to purchase 41,812 shares of Maxygen common stock; the acquisition will be accounted for as a purchase |
| Protana A/S (Denmark) | MDS Proteomics (subsidiary of MDS Inc.; Canada; TSE:MDS) | 9/00 | 4Q:00 | ND | MDS acquired the remaining 50% of MDS Protana in exchange for MDS Proteomics shares |
| Proteome Inc. | Incyte Genomics Inc. (INCY) | 12/00 | 12/00 | $77 | Incyte paid $77M in a combination of cash and equity, in exchange for all of Proteome s outstanding capital stock |
| Quay Pharmaceuticals (Australia) | Cellegy Pharmaceuticals Inc. (CLGY) | 4/00 | 6/00 | $1.80 | Cellegy Pharmaceuticals completed the acquisition of Quay for 0.17M shares of unregistered common stock, 17,146 warrants to purchase common stock and cash payments of $0.37M |
| Quorum Sciences Inc. | Aurora Biosciences Corp. (ABSC) | 10/00 | 10/00 | $3.80 | Aurora acquired Quorum Sciences for 81,287 shares of Aurora common stock; merger was accounted for using the pooling-of-interests method; the value of the transaction, $3.8M, is based on the Oct. 20 stock opening price of $47 |
| Research Genetics Inc. | Invitrogen Corp. (IVGN) | Jun-99 | 2/00 | $220.80 | Invitrogen acquired Research Genetics for 3.2M Invitrogen shares; on the date of closing, 2/2/00, Invitogren shares closed at $69 per share, giving the deal a value of $220.8M; Invitrogen also issued up to 750,000 shares via options given to Research Genetics employees; the transaction was accounted for as a pooling of interests and qualified as a tax-free exchange |
| Renaissance Cell Technologies Inc. and Aeolus Pharmaceuticals Inc. (both subsidiaries of Incara Pharmaceuticals Corp.; INCR) | Incara Pharmaceuticals Corp. (ICNR) | 3/00 | 3/00 | $6.90 | Incara previously owned 78% of Renaissance and 66% of Aeolus; the company acquired the remaining interests of both companies through issuance of 1.2M shares of stock, valued at $6.9M based on 3/31 closing price of $5.75 per share |
| Segix Italia (Italy) | Elan Corp. plc (Ireland; NYSE:ELN) | 5/00 | 5/00 | ND | Elan Corp. completed the acquisition of Segix Italia, based in Pomezia, Italy |
| Serex Inc. | Nymox Pharmaceutical Corp. (NYMX) | 1/00 | 3/00 | $2.60 | Nymox acquired majority ownership of Serex for 0.26M shares and 0.16M warrants exercisable at $3.70 each; the share component is worth $2.6M based on the 3/8/00 closing price of Nymox stock, $9.938 |
| Shanghai Genecore Biotechnologies Co. Ltd. (China) | Celera Genomics Group (NYSE:CRA) | 1/00 | 1/00 | ND | Celera acquired 47.5% of the equity in Shanghai, a stake formerly held by Axys Pharmaceuticals Inc. (AXPH); Celera's sister company, PE Biosystems Group (NYSE:PEB), also owns 47.5% interest, giving parent firm PE Corp. a 95% stake |
| Signal Pharmaceuticals Inc. | Celgene Corp. (CELG) | 6/00 | 9/00 | $277 | Celgene acquired all outstanding Signal shares in a tax-free stock-for-stock merger, issuing 3.7M shares of common stock in exchange for all of the outstanding capital stock of Signal; the exchange ratio is 0.1257 Celgene shares for each share of Signal; the shares Celgene issued as part of the transaction represent 4.4 percent of the company s total shares outstanding |
| Small Molecule Therapeutics Inc. | Morphochem AG (Germany) | 3/00 | 3/00 | ND | Morphochem and SMT will become a fully integrated company with SMT a wholly owned U.S. subsidiary called Morphochem Inc.; transaction was structured as a triangle reverse merger in which Morphochem AG acquired 100% of the shares of SMT for cash and stock; following the transaction, SMT's leading shareholders (Domain Associates, Mayfield and 3i) now hold 8% of Morphochem stock; the deal was led by Techno Venture Management, Morphochem's lead investor |
| Solco Basel AG (Switzerland) | ICN Pharmaceuticals Inc. (NYSE:ICN) | 7/00 | 7/00 | ND | Terms of the transaction were ND: Solco had $28M in sales in 1999, and also brings into the ICN fold a manufacturing facility in Basel, Switzerland, and a 250-person staff |
| Spiros Development Corp. II Inc. (SDCO) | Dura Pharmaceuticals Inc. (DURA) | 2/00 | 8/00 | $106 | Dura paid $13.25 in cash for each share of Spiros stock, plus one five-year warrant, with a calculated value of $3.22, to purchase 0.19 shares of Dura common stock exercisable at $17.94 per share; the new Dura warrants will be traded as DURAZ on Nasdaq |
| Strata Biosciences | GeneTrace Systems Inc. | 3/00 | 3/00 | ND | GeneTrace closed a Series B financing in conjunction with the acquisition and consolidated operations at GeneTrace's facilities in Alameda, Calif. |
| STC Technologies Inc. | Epitope Inc. (EPTO) | 5/00 | 9/00 | $260 | Epitope merged with STC, whose shareholders received about 19.3M shares of Epitope; the combined company is renamed OraSure Technologies Inc. (OSUR) and is headquartered in Bethlehem, Pa.; the transaction will be accounted for as a tax-free pooling of interests; Epitope will issue one new share of OraSure stock for each outstanding share of Epitope |
| Synergy Pharmaceuticals Inc. | United Therapeutics Corp. (UTHR) | 3/00 | 3/00 | ND | As part of licensing agreement for antiviral compounds, United acquired a 15% stake in Synergy with an option to acquire the remainder |
| Synopsys Scientific Systems Ltd. | Pharmacopeia Inc. (PCOP) | 2/00 | 2/00 | $25 | Pharmacopeia acquired all of Synopsys' outstanding stock in a transaction valued at approximately $25M, consisting primarily of cash |
| Synthetic Genetics | Epoch Biosciences Inc. (EBIO) | 11/00 | 11/00 | $3.10 | Epoch acquired Synthetic Genetics from the Immune Complex Corp. for $3.1M in cash |
| t. Breeders Inc. | Viacord Inc. | 4/00 | 4/00 | ND | The companies merged to form ViaCell Inc., which raised $11M from three venture capital firms (MPM Asset Management, Javelin Capital and Zero Stage Capital) upon closing of the agreement; the company will maintain two facilities |
| Talaria Therapeutics Inc. | Esperion Therapeutics Inc. (ESPR) | 10/00 | 10/00 | $7.20 | Esperion acquired all outstanding Talaria shares of common stock for 813,000 shares of Experion stock; Esperion will make payments to Talaria stockholders on milestones and royalties on net sales of large unilamellar vesicles technology acquired in the merger; the acquisition and an amendment to be executed to an existing license agreement with Inex Pharmaceuticals Corp. successfully resolves the litigation that Talaria and Dr. Kevin Williams brought against Esperion, Inex and other parties |
| TerraGen Discovery Inc. | Cubist Pharmaceuticals Inc. (CBST) | 8/00 | 10/00 | $29 | Cubist completed the acquisition of TerraGen Discovery by acquiring 100% of TerraGen shares in a stock-for-stock merger; Cubist mitted to making a tender offer to purchase the 608,000 shares |
| ThermoGen Inc. | MediChem Research Inc. | 6/00 | 6/00 | ND | MediChem, currently in registration for an IPO, acquired ThermoGen for 0.185M shares of common stock and the assumption of options to purchase 25,486 shares of common stock |
| Tyrogene Biotechnologies Inc. (Canada) | Kinetek Pharmaceuticals Inc. (Canada) | 3/00 | 3/00 | ND | Kinetek acquired Tyrogene and its assets and expertise for the development of protein tyrosine phosphates |
| Verex Laboratories Inc. (VRXL) | PR Pharmaceuticals Inc. | Dec-99 | 3/00 | ND | PR purchased 52.95% of Verex's outstanding common stock from certain shareholders and directors, each of whom received one share of PR for each 15 shares of Verex; PR has com remaining shares on a similar exchange basis or, at PR's option, for a cash purchase price |
| Viral Antigens Inc. | Meridian Diagnostics Inc. (KITS) | 9/00 | 9/00 | $9 | Meridian acquired all outstanding Viral Antigens capital stock in cash and earnout opportunities over the next 6 years; Viral Antigen s management will remain intact |
| Vysis Sarl (French subsidiary of Vysis Inc.; VYSI) | Applied Genetic Services Ltd. (UK) | 2/00 | 2/00 | $1.20 | Vysis sold its wholly owned French subsidiary, Vysis Sarl, for $1.2M; in conjunction with the sale, AGS was appointed Vysis' exclusive French distributor for several product lines, with a separate deal for distribution of clinical in vitro diagnostic products under discussion |
| Xtrana Inc. | Biopool International Inc. (OTC BB:BIPL) | 5/00 | 8/00 | $9.70 | Biopool issued an aggregate of 9.4M shares of common stock in exchange for all Xtrana common and preferred stock; former shareholders of Xtrana own 50 percent of the merged company |
II. PENDING
| Company Acquired (Symbol/ Country) | Acquired By or Merged With (Symbol/ Country) | Month Announced | Expected Completion | Value (M)* | Terms/Details |
| BioChem Pharma Inc. (Canada; BCHM) | Shire Pharmaceuticals Group plc (UK; SHPGY) | 12/00 | 2Q:01 | $4B | BioChem shareholders will get $37 worth of Shire consideration shares per BioChem provided the average closing price of a Shire American depository share is between $47.20 and $70.80 during a 15-trading day period |
| bioMerieux Group (France) | Pierre Fabre Group (France) | 9/00 | 1/01 | ND | The combined bioMerieux-Pierre Fabre Group will be owned equally by the two founding groups, combining diagnostics and therapeutics and controlling the entire research and development process; the group is expected to consider a public stock listing in due course; financial terms were ND |
| Bradford Particle Design plc (UK) | Inhale Therapeutic Systems Inc. (INHL) | 12/00 | 1/01E | $200 | Inhale made a $200M offer to acquire Bradford; the offer is $180M in newly issued Inhale stock and $20M in cash; the offer involves about 3.7M shares |
| Bunsen Rush Laboratories Inc. | Arena Pharmaceuticals Inc. (ARNA) | 12/00 | 02/01 | $15 | Arena has agreed to acquire all of the outstanding capital stock of Bunsen Rush in an all-cash transaction for $15M |
| Canberra Industries (unit of Packard BioScience Co.; PBSC) | Cogema (France) | 11/00 | 1Q:00 | $170 | Packard agreed to sell Canberra to Cogena for $170M; Canberra will remain at its Connecticut headquarters under the existing management |
| Carcinotek Inc. | ECCO Capital Corp. (Pink Sheets: ECCP) | 10/00 | 12/00 | $22.60 | ECCO signed a letter of intent to purchase Carcinotek for $22.6M in cash and stock |
| Chesapeake Biological Laboratories Inc. (Canada; CBLI) | Cangene Corp. (Canada; TSE:CNJ) | 10/00 | 1/01 | $31.30 | Cangene said its tender offer to purchase all of the outstanding shares of Chesapeake will expire 1/3; it has tendered more than 6.8M shares, 93% of the company; shareholders who do not tender their shares will receive $4.60 per share in cash |
| Cooke Pharma Inc. | United Therapeutics Corp. (UTHR) | 12/00 | 1Q:01E | $4.70 | United s subsidiary, Unither Pharmaceuticals Inc., is acquiring all the assets of Cooke Pharma for 300,000 shares of stock, which were valued at $4.7M as of Dec. 18 |
| Cytomatrix LLC | Select Therapeutics Inc. (AMEX:XZL) | 7/00 | 1Q:02E | ND | Select can acquire Cytomatrix in a tax-free exchange of shares from Feb. 1, 2001, to July 31, 2002 |
| Eligix Inc. | BioTransplant Inc. (BTRN) | 12/00 | 1Q:01 | $55 | BioTransplant will issue 6.6M shares of its common stock to Eligix shareholders |
| Epigenomics AG (Germany) | ORCA Biosciences Inc. | 12/00 | 1Q:01 | ND | Epigenomics said it will merge with ORCA and the transaction has been approved by both boards of directors |
| Fundamental Forces Corp. | Genomic Solutions Inc. (GNSL) | 10/00 | 2Q:01 | ND | Genomic Solutions said it signed a six-month option agreement to purchase all outstanding shares of Fundamental, in exchange for stock and cash |
| Molecular BioSystems Inc. (OTC BB:MBIO) | Alliance Pharmarceutical Corp. (ALLP) | 10/00 | 1/01 | ND | Alliance will acquire all shares of Molecular Biosystems in exchange for 770,000 shares of Alliance stock, with Molecular becoming a wholly owned subsidiary |
| NeuroVir Therapeutics Inc. | MediGene AG (Germany) | 11/00 | 1/01 | $77 | MediGene will acquire NeuroVir in an all-stock deal valued at about $77M |
| New Chemical Entities Inc. | Albany Molecular Research Inc. (AMRI) | 12/00 | 1/01 | $22.40 | AMRI will acquire NCE for $22.4M and will assume about $600,000 in outstanding debt |
| PanVera Corp. | Aurora Biosciences Corp. (ABSC) | 11/00 | 1Q:01E | $86 | PanVera stockholders will receive about 1.34 shares of Aurora stock for each share of PanVera stock, and Aurora will issue a total of 1.9M shares |
| Pathology Associates International Corp. (unit of Science Applications International Corp.) | Charles River Laboratories International Inc. (NYSE:CRL) | 12/00 | 1/01 | $37 | Charles River will acquire Pathology Associates for $25M in cash and a $12M convertible note |
| ProBio Inc. | Pharming Group NV (the Netherlands; Easdaq:PHAR) | 11/00 | 1Q:01 | $8 | Pharming will issue ordinary shares for US$4M and will make milestone payments of US$4M to ProBio shareholders over the next two years; the acquisition is conditional upon Pharming raising funds to support ProBio s operational expenses |
| RGS Genome Inc. (Canada) | Xenon Genetics Inc. | 11/00 | 1Q:01 | ND | Xenon signed a deal to buy out RGS for an undisclosed amount; Xenon acquires all outstanding shares of RGS in exchange for cash and Xenon shares |
| Systems Integration Drug Discovery Co. Inc. | Discovery Partners International Inc. (DPII) | 12/00 | 1/01 | ND | Discovery Partners signed a definitive agreement to purchase Systems Integration |
| Trega Biosciences Inc. (TRGA) | LION Bioscience AG (Germany; LEON) | 12/00 | 3/01 | $35 | LION has agreed to acquire Trega in exchange for LION American depositary shares at $1.35 per share |
III. TERMINATED
| Company Acquired (Symbol/ Country) | Acquired By or Merged With (Symbol/ Country) | Month Announced | Month Completed | Value (M)* | Terms/Details |
| Advanced Magnetics Inc. (AMEX:AVM) | Cytogen Corp. (CYTO) | 7/00 | 8/00 | $60 | Cytogen was to acquire all of Advanced Magnetics outstanding stock in a tax-free, stockfor-stock transaction structured as a pooling of interests; the companies mutually terminated the merger and entered into marketing, license and supply agreements, agreeing that the advantages of a marketing and supply arrangement outweighed the near-term benefits of the merger |
| Biotech International (Australia; ASX:BII) | Peptech Ltd. (Australia; ASX:PTD) | 12/99 | 5/00 | ND | Peptech was to buy Biotech through a stock swap, creating a company with A$62M (US$41.5M) in assets; due to a ruling by the Supreme Court of Western Australia finding noncompliance of two procedures involved in the provision of copies of notices, and, accordingly, the merger offer had not been declared unconditional; Peptech will not be acquiring any shares from Biotech International share holders who had accepted Peptech's offer |
| Gliatech Inc. (GLIA) | Guilford Pharmaceuticals Inc. (GLFD) | 5/00 | 8/00 | $203 | Guilford was to acquire Gliatech in exchange for all of the outstanding common stock of Gliatech; the companies agreed to a mutual termination, based primarily on the FDA inspection results in a Form 483 report, identifying identifying certain items pertaining to the recording of and the process of recording and presenting data to the FDA with respect to a U.S. clinical trial of Gliatech s ADCON-L |
| Hypernix Technologies Inc. (Israel) | Siga Technologies Inc. (SIGA) | 6/00 | 8/00 | $14.40 | After the proposed merger was announced, various circumstances and alternatives developed that made Siga re-examine whether the deal was in its best interests; Siga was to have acquired the company with 3M shares of its common stock (worth $14.4M on the date of the announcement), plus the assumption of $1.25M in liabilities; the agreement was terminated |
| Innovative Drug Delivery Systems | Meteor Industries Inc. (METR) | 6/00 | 10/00 | ND | Meteor Industries entered into a nonbinding letter of intent to acquire all of the outstanding shares of Innovative Drug Delivery Systems; the agreement was terminated |
| Molecular Biosystems Inc. (OTC BB:MBIO) | Palatin Technologies Inc. (AMEX:PTN) | 11/99 | 3/00 | $27 | Palatin said it would not extend the merger consummation date of 3/31/00, and, in fact, would not complete the merger due to management's opinion that the merger is not currently in the best interests of its stockholders |
| Nova Molecular Inc. (Canada) | SignalGene Inc. (Canada; TSE:SGI) | 8/00 | 9/00 | C$6.9 (US$4.7) | After announcing the proposed merger and performing a review of Nova, SignalGene concluded that the proposed merger was not appropriate |
| Peptide Therapeutics plc (UK; LSE:PTE) | Cantab Pharmaceuticals plc (UK; LSE:CTB; CNTBY) | 7/00 | 9/00 | ND | After the proposed merger was announced, the companies were not able to agree on terms, and following Peptide s strategic alliance with Baxter Healthcare Corp., in which Baxter acquired a 20% stake in Peptide, the merger talks were terminated |
| Quadrant Healthcare plc (UK; LSE:QTH) | Inhale Therapeutic Systems Inc. (INHL) | 10/00 | 11/00 | $60.60 | Inhale was to acquire Quadrant in an all-cash offer for all outstanding shares of Quadrant; merger was terminated due to a higher competitive bid from another company for Quadrant |
| Third Wave Technologies Inc. (TWTI) | PE Biosystems Group (NYSE:PEB) | 1/00 | 5/00 | $330 | PE Biosystems was to acquire Third Wave Technologies in exchange for PE Biosytems Group stock; the companies agreed after to terminate the merger agreement; both companies concluded that their collective interests would be best served if they remain independent but continue to collaborate |
| Vernalis plc (UK; formerly Vanguard Medica Group) | CeNeS Pharmaceuticals plc (UK; LSE:CEN) | 4/00 | 5/00 | N/A | The merger was called off due to differences on management and valuation issues |
| Notes: This chart is intended to include not only mergers and acquisitions of entire businesses, but also of divisions or subsidiaries of those businesses, where appropriate. It does not include acquistions of single products or of manufacturing facilities and plants. It does not include mergers and acquisitions in the area of agricultural biotechnology. For those deals that are pending, and for which the acquiring company is issuing stock, the value of the transaction has been calculated based on the closing price on the day of the first announcement. For those deals that have been completed, and for which the acquiring company is issuing stock, the final value has been calculated based on the closing price on the date that the merger's completion was announced. The chart covers the time between 1/1/00 and 12/31/00; stocks trade on NASDAQ unless otherwise noted. AMEX = American Stock Exchange; ASE = Australian Stock Exchange Limited; CNDX = Canadian Venture Exchange; Easdaq = Pan-European Exchange; LSE = London Stock Exchange; MSE = Montreal Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange ND = Not disclosed, reported and/or available E = Estimated date, dependent on approval of regulatory authorities and shareholders of one or all companies involved in the transaction. * Conversions of non-U.S. currencies are calculated using the rate on the date the transaction closed, or for pending deals, on the date it was announced. | |||||